EntreMed (ENMD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tom R. Clarksburg who wrote (510)	5/4/1998 7:00:00 PM
From: BARRY ALLEN	Read Replies (2) of 2135

Ever hear of Advanced Viral Research(ADVR)? Their flagship drug, Reticulose, is also under study by the NCI. Here is an excerpt of that announcement. They are already doing PhaseIII human trials in Argentina on AIDS and Herpes/HPV! "Reticulose is a non-toxic immunomodulator that has been shown to have a broad spectrum of antiviral therapeutic effects in patients. At the NCI, Reticulose is being used to study the basic mechanisms of immune responses. This scientific research is led by Dr. Howard Young, Section Chief in the Laboratory of Experimental Immunology at the NCI, an expert on interferon-gamma. Using kidney tumor model systems, Dr. Young is investigating the anti-tumor activity of Reticulose. In addition, Dr. Young and his colleagues will study the effects of Reticulose on inflammation associated with rheumatoid arthritis." biz.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next